JP2020531425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531425A5 JP2020531425A5 JP2020508427A JP2020508427A JP2020531425A5 JP 2020531425 A5 JP2020531425 A5 JP 2020531425A5 JP 2020508427 A JP2020508427 A JP 2020508427A JP 2020508427 A JP2020508427 A JP 2020508427A JP 2020531425 A5 JP2020531425 A5 JP 2020531425A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrazol
- benzenesulfonamide
- hydroxyethyl
- methyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyanomethyl Chemical group 0.000 claims 70
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 32
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 6
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 3
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 229960003804 efavirenz Drugs 0.000 claims 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 claims 2
- 206010062207 Mycobacterial infection Diseases 0.000 claims 2
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims 2
- 229950005846 amdoxovir Drugs 0.000 claims 2
- 239000003926 antimycobacterial agent Substances 0.000 claims 2
- 229940121383 antituberculosis agent Drugs 0.000 claims 2
- 229960002656 didanosine Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229960002049 etravirine Drugs 0.000 claims 2
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229960003350 isoniazid Drugs 0.000 claims 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 2
- 229960000689 nevirapine Drugs 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 239000000814 tuberculostatic agent Substances 0.000 claims 2
- 150000003952 β-lactams Chemical class 0.000 claims 2
- ICFDDEJRXZSWTA-KJFVXYAMSA-N (1s,5s,8as,8br)-1-[(1r)-1-hydroxyethyl]-5-methoxy-2-oxo-5,6,7,8,8a,8b-hexahydro-1h-azeto[1,2-b]isoindole-4-carboxylic acid Chemical compound OC(=O)C1=C2[C@@H](OC)CCC[C@@H]2[C@H]2N1C(=O)[C@@H]2[C@@H](C)O ICFDDEJRXZSWTA-KJFVXYAMSA-N 0.000 claims 1
- HBUJYEUPIIJJOS-PBHICJAKSA-N (5r)-3-[4-[1-[(2s)-2,3-dihydroxypropanoyl]-3,6-dihydro-2h-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one Chemical compound C1N(C(=O)[C@@H](O)CO)CCC(C=2C(=CC(=CC=2F)N2C(O[C@@H](COC3=NOC=C3)C2)=O)F)=C1 HBUJYEUPIIJJOS-PBHICJAKSA-N 0.000 claims 1
- ZLHZLMOSPGACSZ-NSHDSACASA-N (6s)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O([C@H]1CN2C=C(N=C2OC1)[N+](=O)[O-])CC1=CC=C(OC(F)(F)F)C=C1 ZLHZLMOSPGACSZ-NSHDSACASA-N 0.000 claims 1
- QRPZBKAMSFHVRW-UHFFFAOYSA-N 1-(4-benzoylpiperazin-1-yl)-2-[4-methoxy-7-(3-methyl-1,2,4-triazol-1-yl)-1h-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione Chemical compound C1=2NC=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 QRPZBKAMSFHVRW-UHFFFAOYSA-N 0.000 claims 1
- OKGPFTLYBPQBIX-CQSZACIVSA-N 1-[(2r)-4-benzoyl-2-methylpiperazin-1-yl]-2-(4-methoxy-1h-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione Chemical compound C1=2C(OC)=CC=NC=2NC=C1C(=O)C(=O)N([C@@H](C1)C)CCN1C(=O)C1=CC=CC=C1 OKGPFTLYBPQBIX-CQSZACIVSA-N 0.000 claims 1
- KIMCGLHTSSZPNS-UHFFFAOYSA-N 2,3-dinitrobenzamide Chemical compound NC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O KIMCGLHTSSZPNS-UHFFFAOYSA-N 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- GTUIRORNXIOHQR-VIFPVBQESA-N 2-[(3s)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one Chemical compound O1[C@@H](C)COC11CCN(C=2SC3=C([N+]([O-])=O)C=C(C=C3C(=O)N=2)C(F)(F)F)CC1 GTUIRORNXIOHQR-VIFPVBQESA-N 0.000 claims 1
- BJDZBXGJNBMCAV-UHFFFAOYSA-N 2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC(C(N=2)=O)=C1SC=2N(CC1)CCN1CC1CCCCC1 BJDZBXGJNBMCAV-UHFFFAOYSA-N 0.000 claims 1
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 1
- VMWKDHXOEVMTHN-UHFFFAOYSA-N 4-[2-[(4-fluorophenyl)methyl]tetrazol-5-yl]-N-methylbenzenesulfonamide Chemical compound FC1=CC=C(CN2N=C(N=N2)C2=CC=C(C=C2)S(=O)(=O)NC)C=C1 VMWKDHXOEVMTHN-UHFFFAOYSA-N 0.000 claims 1
- CGBYTKOSZYQOPV-ASSBYYIWSA-N 5-chloro-3-[[3-[(e)-2-cyanoethenyl]-5-methylphenyl]-methoxyphosphoryl]-1h-indole-2-carboxamide Chemical compound C1([P@](=O)(C=2C3=CC(Cl)=CC=C3NC=2C(N)=O)OC)=CC(C)=CC(\C=C\C#N)=C1 CGBYTKOSZYQOPV-ASSBYYIWSA-N 0.000 claims 1
- 206010060976 Bacillus infection Diseases 0.000 claims 1
- NZHRWCHXZZTFGN-UHFFFAOYSA-N C(#N)C1=CC=C(CN2N=C(N=N2)C2=CC(=C(C=C2)S(=O)(=O)NCCO)OC)C=C1 Chemical compound C(#N)C1=CC=C(CN2N=C(N=N2)C2=CC(=C(C=C2)S(=O)(=O)NCCO)OC)C=C1 NZHRWCHXZZTFGN-UHFFFAOYSA-N 0.000 claims 1
- RQSCGMPEYMHNFN-UHFFFAOYSA-N C(#N)C1=CC=C(CN2N=C(N=N2)C2=CC=C(C=C2)S(=O)(=O)NC)C=C1 Chemical compound C(#N)C1=CC=C(CN2N=C(N=N2)C2=CC=C(C=C2)S(=O)(=O)NC)C=C1 RQSCGMPEYMHNFN-UHFFFAOYSA-N 0.000 claims 1
- 108010036239 CD4-IgG(2) Proteins 0.000 claims 1
- JJEGOJPMKLRSPJ-POURPWNDSA-N COc1cc(cc(OC)n1)[C@](O)(CCN(C)C)[C@H](c1cccc(OC)c1F)c1cc2cc(Br)ccc2nc1OC Chemical compound COc1cc(cc(OC)n1)[C@](O)(CCN(C)C)[C@H](c1cccc(OC)c1F)c1cc2cc(Br)ccc2nc1OC JJEGOJPMKLRSPJ-POURPWNDSA-N 0.000 claims 1
- KAKICEJZEZVQCA-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C=1N=NN(N=1)CC1=NC=C(C=C1)F)C)S(=O)(=O)NCCO Chemical compound FC1=C(C=C(C(=C1)C=1N=NN(N=1)CC1=NC=C(C=C1)F)C)S(=O)(=O)NCCO KAKICEJZEZVQCA-UHFFFAOYSA-N 0.000 claims 1
- ROCJMGUQWVOKBT-UHFFFAOYSA-N FC1=CC=C(CN2N=C(N=N2)C2=CC(=C(C=C2)S(=O)(=O)NCCO)OC)C=C1 Chemical compound FC1=CC=C(CN2N=C(N=N2)C2=CC(=C(C=C2)S(=O)(=O)NCCO)OC)C=C1 ROCJMGUQWVOKBT-UHFFFAOYSA-N 0.000 claims 1
- ZNBRXLSWXJKKLJ-LBPRGKRZSA-N FC=1C=C(C=CC=1N1CC2(COC2)C1)N1C(O[C@H](C1)CNC(OC)=O)=O Chemical compound FC=1C=C(C=CC=1N1CC2(COC2)C1)N1C(O[C@H](C1)CNC(OC)=O)=O ZNBRXLSWXJKKLJ-LBPRGKRZSA-N 0.000 claims 1
- CMJUUQUYVVLHDE-UHFFFAOYSA-N FC=1C=CC(=NC=1)CN1N=C(N=N1)C1=CC(=C(C=C1)S(=O)(=O)NCCO)OC Chemical compound FC=1C=CC(=NC=1)CN1N=C(N=N1)C1=CC(=C(C=C1)S(=O)(=O)NCCO)OC CMJUUQUYVVLHDE-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 229960004748 abacavir Drugs 0.000 claims 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000001355 anti-mycobacterial effect Effects 0.000 claims 1
- 230000000798 anti-retroviral effect Effects 0.000 claims 1
- 229940034014 antimycobacterial agent Drugs 0.000 claims 1
- 229940124522 antiretrovirals Drugs 0.000 claims 1
- 239000003903 antiretrovirus agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940098164 augmentin Drugs 0.000 claims 1
- 229960000508 bedaquiline Drugs 0.000 claims 1
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229940090805 clavulanate Drugs 0.000 claims 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229960003496 delamanid Drugs 0.000 claims 1
- XDAOLTSRNUSPPH-XMMPIXPASA-N delamanid Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-XMMPIXPASA-N 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- XNHZXMPLVSJQFK-UHFFFAOYSA-O dimethyl-[[4-[[3-(4-methylphenyl)-8,9-dihydro-7h-benzo[7]annulene-6-carbonyl]amino]phenyl]methyl]-(oxan-4-yl)azanium Chemical compound C1=CC(C)=CC=C1C1=CC=C(CCCC(=C2)C(=O)NC=3C=CC(C[N+](C)(C)C4CCOCC4)=CC=3)C2=C1 XNHZXMPLVSJQFK-UHFFFAOYSA-O 0.000 claims 1
- 229960002542 dolutegravir Drugs 0.000 claims 1
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims 1
- 229960003586 elvitegravir Drugs 0.000 claims 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 claims 1
- 229960002001 ethionamide Drugs 0.000 claims 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 1
- SWMDAPWAQQTBOG-UHFFFAOYSA-N fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 claims 1
- 229950010812 fostemsavir Drugs 0.000 claims 1
- 208000006278 hypochromic anemia Diseases 0.000 claims 1
- 229950010245 ibalizumab Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960001627 lamivudine Drugs 0.000 claims 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims 1
- 229940121292 leronlimab Drugs 0.000 claims 1
- 229960003907 linezolid Drugs 0.000 claims 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims 1
- 229960004710 maraviroc Drugs 0.000 claims 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 1
- 229960002260 meropenem Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims 1
- 229960003702 moxifloxacin Drugs 0.000 claims 1
- VDRYGTNDKXIPSK-UHFFFAOYSA-N n-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound COC1=NC=NC(CN2C3=CC(C)=CN=C3C(C(=O)NCCO)=C2)=C1C VDRYGTNDKXIPSK-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960000918 protionamide Drugs 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 229960001225 rifampicin Drugs 0.000 claims 1
- 229960002599 rifapentine Drugs 0.000 claims 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims 1
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims 1
- 229960000311 ritonavir Drugs 0.000 claims 1
- 229950010458 sanfetrinem Drugs 0.000 claims 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims 1
- FNDDDNOJWPQCBZ-ZDUSSCGKSA-N sutezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCSCC1 FNDDDNOJWPQCBZ-ZDUSSCGKSA-N 0.000 claims 1
- 229960003879 tedizolid Drugs 0.000 claims 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims 1
- 229960003231 thioacetazone Drugs 0.000 claims 1
- BWBONKHPVHMQHE-UHFFFAOYSA-N tiocarlide Chemical group C1=CC(OCCC(C)C)=CC=C1NC(=S)NC1=CC=C(OCCC(C)C)C=C1 BWBONKHPVHMQHE-UHFFFAOYSA-N 0.000 claims 1
- 229960002171 tiocarlide Drugs 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 229960002555 zidovudine Drugs 0.000 claims 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382574 | 2017-08-17 | ||
| EP17382574.6 | 2017-08-17 | ||
| PCT/EP2018/072205 WO2019034729A1 (en) | 2017-08-17 | 2018-08-16 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531425A JP2020531425A (ja) | 2020-11-05 |
| JP2020531425A5 true JP2020531425A5 (https=) | 2021-09-24 |
| JP7410017B2 JP7410017B2 (ja) | 2024-01-09 |
Family
ID=59713960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508427A Active JP7410017B2 (ja) | 2017-08-17 | 2018-08-16 | 新規なテトラゾール化合物および結核の治療におけるそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11072591B2 (https=) |
| EP (1) | EP3668856B1 (https=) |
| JP (1) | JP7410017B2 (https=) |
| KR (1) | KR102661367B1 (https=) |
| CN (1) | CN110997651B (https=) |
| AU (1) | AU2018317812C1 (https=) |
| CA (1) | CA3072854A1 (https=) |
| CY (1) | CY1124577T1 (https=) |
| DK (1) | DK3668856T3 (https=) |
| ES (1) | ES2885573T3 (https=) |
| HR (1) | HRP20211326T1 (https=) |
| HU (1) | HUE055732T2 (https=) |
| LT (1) | LT3668856T (https=) |
| PL (1) | PL3668856T3 (https=) |
| PT (1) | PT3668856T (https=) |
| RS (1) | RS62267B1 (https=) |
| SI (1) | SI3668856T1 (https=) |
| SM (1) | SMT202100515T1 (https=) |
| WO (1) | WO2019034729A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184718A (zh) * | 2018-11-15 | 2020-05-22 | 鲁南制药集团股份有限公司 | 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途 |
| CN115403533B (zh) * | 2021-05-28 | 2023-08-25 | 永康市第一人民医院 | 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用 |
| CN116102483B (zh) * | 2021-11-09 | 2025-01-17 | 中国医学科学院药物研究所 | 取代吡咯-2,5-二酮类化合物及其制备方法和用途 |
| CN116726018A (zh) * | 2023-08-02 | 2023-09-12 | 上海市肺科医院（上海市职业病防治院） | 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用 |
| CN117379430A (zh) * | 2023-10-11 | 2024-01-12 | 深圳市第三人民医院(深圳市肝病研究所) | 一种地拉韦啶的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3621427B2 (ja) | 1997-07-22 | 2005-02-16 | 塩野義製薬株式会社 | 糸球体障害治療または予防剤 |
| KR20120003499A (ko) * | 2007-04-05 | 2012-01-10 | 지멘스 메디컬 솔루션즈 유에스에이, 인크. | 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조 |
| WO2017066964A1 (en) | 2015-10-22 | 2017-04-27 | Merck Sharp & Dohme Corp. | Oxazolidinone compounds and methods of use thereof as antibacterial agents |
-
2018
- 2018-08-16 WO PCT/EP2018/072205 patent/WO2019034729A1/en not_active Ceased
- 2018-08-16 ES ES18755815T patent/ES2885573T3/es active Active
- 2018-08-16 HR HRP20211326TT patent/HRP20211326T1/hr unknown
- 2018-08-16 US US16/639,163 patent/US11072591B2/en active Active
- 2018-08-16 PT PT187558150T patent/PT3668856T/pt unknown
- 2018-08-16 JP JP2020508427A patent/JP7410017B2/ja active Active
- 2018-08-16 SM SM20210515T patent/SMT202100515T1/it unknown
- 2018-08-16 EP EP18755815.0A patent/EP3668856B1/en active Active
- 2018-08-16 CN CN201880053320.XA patent/CN110997651B/zh active Active
- 2018-08-16 CA CA3072854A patent/CA3072854A1/en active Pending
- 2018-08-16 LT LTEPPCT/EP2018/072205T patent/LT3668856T/lt unknown
- 2018-08-16 SI SI201830348T patent/SI3668856T1/sl unknown
- 2018-08-16 PL PL18755815T patent/PL3668856T3/pl unknown
- 2018-08-16 RS RS20211076A patent/RS62267B1/sr unknown
- 2018-08-16 AU AU2018317812A patent/AU2018317812C1/en active Active
- 2018-08-16 KR KR1020207007186A patent/KR102661367B1/ko active Active
- 2018-08-16 DK DK18755815.0T patent/DK3668856T3/da active
- 2018-08-16 HU HUE18755815A patent/HUE055732T2/hu unknown
-
2021
- 2021-08-31 CY CY20211100770T patent/CY1124577T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531425A5 (https=) | ||
| Nuermberger et al. | Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model | |
| US9133183B2 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2017511329A5 (https=) | ||
| HRP20211326T1 (hr) | Novi spojevi tetrazola i njihova primjena u liječenju tuberkuloze | |
| HRP20191821T1 (hr) | Antiproliferativni spojevi i načini njihove uporabe | |
| RU2013114352A (ru) | Азабензотиазолы, композиции и способы применения | |
| JP2016538313A5 (https=) | ||
| RU2014148316A (ru) | Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы | |
| JP2017523215A5 (https=) | ||
| RU2011137399A (ru) | Гетероциклическое производное | |
| JP2015514679A5 (https=) | ||
| JP2015514794A5 (https=) | ||
| RU2015113746A (ru) | Замещенные сульфонамиды | |
| JP2016523935A5 (https=) | ||
| JP2016523976A5 (https=) | ||
| JP2017534569A5 (https=) | ||
| RU2016132858A (ru) | Производные фторнафтила | |
| JP2019501937A5 (https=) | ||
| RU2017105902A (ru) | Соединения для применения в дегельминтизации | |
| JP2023526505A5 (https=) | ||
| JP2018516982A5 (ja) | 免疫療法用組み合わせ組成物 | |
| JP2023550902A5 (https=) | ||
| JP2005516916A5 (https=) | ||
| JP2014527997A5 (https=) |